SILVER SPRING, Md., May 31, 2011 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights for this week from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as of May 31, 2011.
FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations.
Meetings, Workshops, and Congressional Testimony:Tuesday, 5/31 – The Cellular, Tissue, and Gene Therapies Advisory Committee hears about research programs at the FDA's Center for Drug Evaluation and Research involving biochemistry, therapeutic proteins, molecular oncology, cell biology, and monoclonal antibodies. 2:30 p.m. to 5:15 p.m., National Institutes of Health, 29 Lincoln Drive, Building 29B, Conference Rooms A and B, Bethesda, Md.Press Office Contact: Shelly Burgess, 301-796-4651, email@example.com
Thursday, 6/2 – Center for Devices and Radiological Health Director Jeff Shuren testifies before the Subcommittee on Health Care, District of Columbia, Census and the National Archives of the House Committee on Oversight and Government Reform on "Pathway to FDA Medical Device Approval: Is there a Better Way?" 1:30 p.m., Room 2154, Rayburn House Office Building, Washington, DC.Press Office Contact: Karen Riley, 301-796-4674, firstname.lastname@example.org
Thursday, 6/2 and Friday, 6/3 – Workshop on Seizure Detection, Cognitive Function, and TBI/Concussion Devices: Issues in Their Evaluation. Discussion of approaches and endpoints for clinical studies and how results should be conveyed so that the devices may be used effectively. 8 a.m., Building 31, 10903 New Hampshire, Silver Spring, Md.Press Office Contact: Amanda Sena, 301-796-0393, email@example.com
Monday, 6/6 – The FDA's third public meeting on the Food Safety Modernization Act to discuss implementation of the inspections and compliance provisions of the act. 9 a.m., 10903 New Hampshire Avenue, Building 31, Room 1503, Silver Spring, Md. Registration opens at 7:30 a.m. Seating is limited to 200. Press Office Contact: Doug Karas, 301-796-2805, firstname.lastname@example.org
FDA Office of Public Affairs Contact Information:Call or email FDA Office of Public Affairs, 301-796-4540, email@example.comList of FDA press officers and beats
More Resources:FDA News & Events
FDA Photos (Flickr)
Consumer Health Information
SOURCE U.S. Food and Drug Administration
Subscribe to our Free Newsletters!
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...View All